MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-026-13712-5

Медицинская библиотека · Journal of neurology · 2026

Antithrombotic therapy and risk of intracranial hemorrhage in patients with cerebral cavernous malformations: a multicenter propensity-matched cohort study.

Salim Hamza Adel, Lakhani Dhairya A, Hajjeh Orabi, Essibayi Muhammed Amir, Chen Huanwen, Balar Aneri, Adeeb Nimer, Msherghi Ahmed, Jung Melissa, Dmytriw Adam A, Colasurdo Marco, Malhotra Ajay, Gandhi Dheeraj, Yedavalli Vivek, Ucisik FEymen, Eldaya Rami W, Wintermark Max

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

The safety of antithrombotic therapy in patients with cerebral cavernous malformations (CCMs) without prior intracranial hemorrhage (ICH) remains uncertain.

METHODS

We conducted a retrospective, multicenter, propensity score-matched cohort study using the TriNetX Analytics Platform. Adult patients with CCMs and no prior ICH were included. Patients receiving antithrombotic therapy (antiplatelet or anticoagulant) were compared with those receiving no antithrombotic therapy. The primary outcome was ICH; secondary outcomes included seizures, inpatient readmission, and emergency department (ED) visits. Subgroup analyses evaluated outcomes by antithrombotic class. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated.

RESULTS

Among 8989 eligible patients, 1540 in each group were matched. ICH occurred more frequently in the antithrombotic group (6.3%) than in the no-therapy group (3.9%) (HR 1.77, 95% CI 1.28-2.44; log-rank p < 0.001). Seizures (18.6% vs 10.9%; HR 1.84, 95% CI 1.52-2.23), inpatient readmission (57.3% vs 31.8%; HR 2.38, 95% CI 2.13-2.65), and ED visits (39.3% vs 28.4%; HR 1.70, 95% CI 1.50-1.92) were more common. In subgroup analyses, anticoagulant use increased ICH risk (6.8% vs 3.6%; HR 2.14, 95% CI 1.31-3.51; p = 0.002), whereas antiplatelet use did not (5.2% vs 4.3%; HR 1.24, 95% CI 0.73-2.08; p = 0.424).

CONCLUSIONS

In CCM patients without prior ICH, antithrombotic therapy was associated with increased risk of ICH and other adverse outcomes, primarily driven by anticoagulants.

Для цитирования: Salim Hamza Adel, Lakhani Dhairya A, Hajjeh Orabi, Essibayi Muhammed Amir, Chen Huanwen, Balar Aneri, Adeeb Nimer, Msherghi Ahmed, Jung Melissa, Dmytriw Adam A, Colasurdo Marco, Malhotra Ajay, Gandhi Dheeraj, Yedavalli Vivek, Ucisik FEymen, Eldaya Rami W, Wintermark Max. Antithrombotic therapy and risk of intracranial hemorrhage in patients with cerebral cavernous malformations: a multicenter propensity-matched cohort study.. Journal of neurology. 2026. DOI: 10.1007/s00415-026-13712-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.